Skip to content
10-K

Annual Report

PROVECTUS BIOPHARMACEUTICALS, INC. PVCT

0001641172-25-000993

← back to feed
Filed
Mar 28, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2024 · Dec 31, 2023 419.51M sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$2.57M
Cash And Equivalents FY 2024 · Dec 31, 2023 $76.58K
Stockholders Equity FY 2024 · Dec 31, 2023 −$7.59M
Current Liabilities FY 2024 · Dec 31, 2023 $9.02M
Total Liabilities FY 2024 · Dec 31, 2023 $9.04M
Current Assets FY 2024 · Dec 31, 2023 $1.36M
Total Assets FY 2024 · Dec 31, 2023 $1.45M
Eps Diluted FY 2024 · Dec 31, 2023 −$0.01
Eps Basic FY 2024 · Dec 31, 2023 −$0.01
Sga Expense FY 2024 · Dec 31, 2023 $1.71M
Rd Expense FY 2024 · Dec 31, 2023 $1.75M
Net Income FY 2024 · Dec 31, 2023 −$3.1M
Operating Income FY 2024 · Dec 31, 2023 −$2.9M
Revenue FY 2024 · Dec 31, 2023 $557.71K